-
1 Comment
Cyclacel Pharmaceuticals, Inc is currently in a long term downtrend where the price is trading 12.2% below its 200 day moving average.
From a valuation standpoint, the stock is 94.6% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 71.0.
Cyclacel Pharmaceuticals, Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has dropped by 21.6% to $-3M since the same quarter in the previous year.
Finally, its free cash flow fell by 6.6% to $-1M since the same quarter in the previous year.
Based on the above factors, Cyclacel Pharmaceuticals, Inc gets an overall score of 1/5.
Exchange | F |
---|---|
CurrencyCode | EUR |
ISIN | US23254L6039 |
Sector | Healthcare |
Industry | Biotechnology |
Beta | 0.85 |
---|---|
Market Cap | 183K |
PE Ratio | None |
Target Price | 20.25 |
Dividend Yield | None |
Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced leukemias and solid tumors. It has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. The company was founded in 1996 and is headquartered in Berkeley Heights, New Jersey.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for UXI4.F using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025